Shares of Hikma Pharmaceuticals PLC HIK inched down 0.35% to £19.82 Friday, on what proved to be an all-around favorable ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

Shares of Hikma Pharmaceuticals PLC HIK inched up 0.05% to £19.89 Tuesday, on what proved to be an all-around great trading ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals) ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

( MENAFN - Mid-East Info) Amman, Jordan: Hikma Pharmaceuticals PLC (Hikma, Group), the multinational Pharmaceutical group, ...

Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,921.22 ($24.37) and ...

FDA approves Hikma Pharmaceuticals' generic version of Victoza, a once-daily GLP-1 injection for Type 2 diabetes. Other drugmakers also entering the market.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...